AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by Zacks Investment Research

AcelRx Pharmaceuticals (NASDAQ:ACRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

ACRX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th. ValuEngine raised shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Royal Bank of Canada cut their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, October 13th. Jefferies Group downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $6.21.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down $0.08 during trading hours on Monday, reaching $2.07. 508,000 shares of the company’s stock were exchanged, compared to its average volume of 450,270. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78. AcelRx Pharmaceuticals has a fifty-two week low of $1.55 and a fifty-two week high of $5.75. The company has a market cap of $104.45, a P/E ratio of -1.85 and a beta of 2.96.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). equities analysts predict that AcelRx Pharmaceuticals will post -1.06 earnings per share for the current year.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards acquired 30,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average price of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 28.10% of the company’s stock.

Several hedge funds have recently modified their holdings of ACRX. Perennial Advisors LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $138,000. Virtu KCG Holdings LLC grew its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the period. Geller Family Office Services LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $460,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $530,000. 13.70% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/17/acelrx-pharmaceuticals-acrx-stock-rating-lowered-by-zacks-investment-research.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply